Last reviewed · How we verify
NCT05144399: POET II
Accelerated Treatment of Endocarditis
Phase 4 trial testing Accelerated antibiotic treatment in Endocarditis in 475 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Herlev Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 475 |
| Start date | 1 April 2019 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
- Accelerated antibiotic treatment
- Standard treatment length
Conditions studied
- Endocarditis — all drugs for Endocarditis →
Sponsor
Herlev Hospital
Who can join
18 and older, any sex, with Endocarditis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks one or more types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Furthermore, it poses a significant financial burden on the health systems. Current guidelines fail to use available clinical and paraclinical, data collected from patients (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment. A strategy including these data in treatment algorithms ensures an individualized treatment, targeting the individual patient's course and response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority, RCT study is to investigate the safety and effectiveness of shortening treatment of endocarditis based on the individual patient's initial treatment response, sampling 475 patients, approx. 125 patients with each type of bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05144399
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endocarditis
Currently open trials in the same condition.
- NCT05139589 — The ENDOCARDITIS AUMC Data Collection · recruiting
- NCT05547607 — Clinical and Diagnostic Features of Endocarditis · recruiting
- NCT05146180 — Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis · NA · recruiting
- NCT06403839 — Impact of Preoperative Dental Screening in Reducing Infective Endocarditis Risk in Surgical Valve Replacement Patients · recruiting
- NCT03892174 — Cytokine REmoval in CRitically Ill PAtients Requiring Surgical Therapy for Infective Endocarditis (RECReATE) · NA · recruiting
Other Herlev Hospital trials
Trials by the same sponsor.
- NCT07367412 — Zinc Supplementation and Infections in Older Medical Patients · NA · not yet recruiting
- NCT07171216 — The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bon · NA · recruiting
- NCT07272187 — Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions · recruiting
- NCT07117955 — Platelet-Rich Plasma for Peyronie's Disease · NA · recruiting
- NCT07144046 — Tape Application Protocol for Enhanced Scars · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05144399 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herlev Hospital
- Last refreshed: 18 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05144399.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing